3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Head & Neck
2
CNS
2
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Everolimus
7
lutetium Lu 177 dotatate
3
lanreotide
3
Erlotinib Hydrochloride
3
surufatinib
2
gallium Ga 68 dotatate
2
dactolisib
2
Sunitinib
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Filgrastim
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tislelizumab
1
telotristat ethyl
1
telotristat
1
pertuzumab
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
folfirinox
1
famitinib
1
entinostat
1
arginyllysine
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Temozolomide
1
Surveys and Questionnaires
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
alectinib
×
NET
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts